ArticleInternational journal of trichology
A Comment on Coronavirus Disease 2019 and the Hair.
Article in International journal of trichology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel viral pandemic coronavirus disease 2019 (COVID-19) has sparked uncertainties and controversies as to its origin, epidemiology, and natural course. In this situation, the medical disciplines strive to contribute to a better understanding of the disease with the best available evidence gained from the scientific method of observation and statistics. The study of the cutaneous manifestations of COVID-19 has evolved with the hope that they may be useful as markers for the disease, for prognostication, and further insights into the pathogenesis of the disease manifestations. With regard to the hair, clinicopathological correlations have remained hypothetic. Association of androgenetic alopecia (AGA) and gray hair with COVID-19 severity, COVID-19-associated postinfectious effluvium, scalp allodynia, and stress-induced telogen effluvium have been the objects of speculation. Further in-depth studies are warranted to establish whether COVID-19-associated hair loss is due to the systemic inflammation with fever, or whether the inflammation and/or severe acute respiratory syndrome coronavirus 2 may target the hair follicle. Meanwhile, dermatologic conditions have been investigated as cutaneous markers for elevated mortality risk, including AGA and graying. Ultimately, most have been scrutinized with regard to the accuracy and validity of the statistics and not been found to be convincing in identifying them as independent risk factors. We therefore challenge the proposal of the "Gabrin sign" as an eponym for AGA as a severity risk factor in COVID-19. Moreover, Dr. Frank Gabrin is rather to be remembered for his selfless and courageous service at the front lines of the pandemic than for the stigma of his alopecia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.